These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 3477533)

  • 1. Phase I and pharmacokinetic study of high volume intraperitoneal aclacinomycin-A (Aclarubicin).
    Kerr IG; Archer S; DeAngelis C; Farrell S; Hanna S; McKee J
    Invest New Drugs; 1987; 5(2):171-6. PubMed ID: 3477533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical evaluation of aclacinomycin A for the intraperitoneal treatment of human ovarian carcinoma.
    Louie KG; Hamilton TC; Behrens BC; Grotzinger KR; McKoy WM; Myers CE; Young RC; Ozols RF
    Cancer Chemother Pharmacol; 1986; 18(2):153-6. PubMed ID: 3466726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I trial of aclacinomycin-A. A clinical and pharmacokinetic study.
    Karanes C; Young JD; Samson MK; Smith LB; Franco LA; Baker LH
    Invest New Drugs; 1983; 1(2):173-9. PubMed ID: 6590531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aclacinomycin A. Phase II evaluation in advanced soft tissue sarcoma.
    Pazdur R; Samson MK; Baker LH
    Am J Clin Oncol; 1987 Jun; 10(3):237-9. PubMed ID: 3473924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical phase I study of aclacinomycin A by evaluation of an intermittent intravenous administration schedule.
    Casper ES; Gralla RJ; Young CW
    Cancer Res; 1981 Jun; 41(6):2417-20. PubMed ID: 6940656
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current status of Japanese studies with the new anthracycline antibiotic aclacinomycin A.
    Oki T; Takeuchi T; Oka S; Umezawa H
    Recent Results Cancer Res; 1980; 74():207-16. PubMed ID: 7003659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pharmacokinetic study of aclarubicin. The pharmacokinetics of the preparation and its biologically active metabolites in the blood of rats].
    Geodakian SV; Firsov AA; Fomina IP
    Antibiot Med Biotekhnol; 1987 Oct; 32(10):768-72. PubMed ID: 3480699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor efficacies of aclacinomycin A by oral administration.
    Tsukagoshi S; Tsuruo T; Yamori T; Iida H; Naganuma K; Sakurai Y
    J Pharmacobiodyn; 1980 Oct; 3(10):532-6. PubMed ID: 6937651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II evaluation of aclacinomycin-A in advanced ovarian carcinoma.
    Martino S; Decker DA; Hynes HE; Kresge CL
    Invest New Drugs; 1987 Dec; 5(4):373-4. PubMed ID: 3481362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aclarubicin (aclacinomycin A) and irradiation: evaluation using HeLa cells.
    Miyamoto T; Wakabayashi M; Terasima T
    Radiology; 1983 Dec; 149(3):835-9. PubMed ID: 6580675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aclacinomycin A. Phase II evaluation in bronchogenic squamous-cell carcinoma.
    Pazdur R; Samson MK; Baker LH
    Am J Clin Oncol; 1987 Jun; 10(3):234-6. PubMed ID: 3473923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Intravesical instillation therapy of aclacinomycin-A (ACM) for superficial bladder tumor].
    Noguchi S; Kubota Y; Shuin T; Miura T; Moriyama M; Sakuramoto T; Oshima H
    Hinyokika Kiyo; 1984 Sep; 30(9):1153-8. PubMed ID: 6596878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lethal effect of aclacinomycin A on cultured mouse L cells.
    Tanabe M; Miyamoto T; Nakajima Y; Terasima T
    Gan; 1980 Oct; 71(5):699-703. PubMed ID: 6939647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pharmacokinetic study of aclarubicin. The distribution of the preparation and its biologically active metabolites in rat tissues].
    Firsov AA; Geodakian SV; Egorov LV; Terent'eva TG
    Antibiot Med Biotekhnol; 1987 Oct; 32(10):773-7. PubMed ID: 3480700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of amino acid uptake and incorporation into proteins in Friend erythroleukemia cells by the anthracycline antitumor antibiotic aclacinomycin A.
    Schaefer A; Boldt J; Westendorf J; Steinheider G; Marquardt H
    Biochem Pharmacol; 1988 Apr; 37(7):1377-82. PubMed ID: 3162677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Experimental study of the antitumor anthracycline antibiotic aclarubicin (aclacinomycin A)].
    Egorov LV; Terent'eva TG; Rudneva NA; Egorenko GG; Ivanitskaia LP
    Antibiot Med Biotekhnol; 1985 Dec; 30(12):918-27. PubMed ID: 3866512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II trial of aclacinomycin-A in advanced squamous cell carcinoma of the head and neck.
    Eckenrode JL; Wheeler RH; Forastiere AA
    Invest New Drugs; 1985; 3(4):389-92. PubMed ID: 3866756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I--II evaluation of a new anthracycline antibiotic, aclacinomycin A, in adults with refractory leukemia.
    Warrell RP; Arlin ZA; Kempin SJ; Young CW
    Cancer Treat Rep; 1982 Aug; 66(8):1619-23. PubMed ID: 6955022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I-II trial of aclacinomycin A given in a four-consecutive-day schedule to patients with solid tumours. A South-East European Oncology Group (SEEOG) Study.
    Kerpel-Fronius S; Gyergyay F; Hindy I; Decker A; Sawinsky I; Fäller K; Mechl Z; Nekulova M; Kolaric K; Tomek R
    Oncology; 1987; 44(3):159-63. PubMed ID: 3474571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancement of immune responses and possible inhibition of suppressor cells by aclacinomycin A.
    Ishizuka M; Takeuchi T; Masuda T; Fukasawa S; Umezawa H
    J Antibiot (Tokyo); 1981 Mar; 34(3):331-40. PubMed ID: 6456249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.